Solange Peters

Solange Peters is a thoracic oncologist who contributed to CHECKMATE-227 demonstrating nivolumab plus ipilimumab as a first-line option for advanced NSCLC based on TMB and PD-L1. She has been chair of the ESMO Scientific Committee and has led the development of ESMO Clinical Practice Guidelines for thoracic malignancies. Her research encompasses predictive biomarkers, novel immunotherapy combinations, and overcoming IO resistance in NSCLC. Peters is recognized internationally for integrating molecular oncology principles into first-line NSCLC treatment selection.